Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CellX (Shanghai Shisaierxin Food Technology) is a leading Chinese biotechnology company specializing in cellular agriculture and the development of cultivated meat. Founded in 2020 and based in Shanghai, the company utilizes advanced cell culture and tissue engineering technologies to produce sustainable animal proteins, including pork, beef, and poultry. CellX has developed a proprietary multi-species technology platform that encompasses cell line development, serum-free media optimization, and large-scale bioreactor scaling. The company recently launched its FX pilot production facility, marking a significant step toward commercial-scale manufacturing. By providing slaughter-free meat alternatives, CellX aims to address global issues such as food security, climate change, and animal welfare. The company is backed by prominent venture capital firms and is actively working with regulators to bring cultivated meat to consumers worldwide.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on 上海赛尔欣.